Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.35+0.12 (+1.93%)
Close on Nov 18, 2026Market cap $680.88MP/E –Yield –
Solid Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Solid Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$212.15M. For fiscal 2025 it was -$179.21M. The highest annual figure on record is -$25.58M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$179.21M | – |
| FY2024 | Dec 31, 2024 | -$129.73M | – |
| FY2023 | Dec 31, 2023 | -$104.25M | – |
| FY2022 | Dec 31, 2022 | -$106.45M | – |
| FY2021 | Dec 31, 2021 | -$72.25M | – |
| FY2020 | Dec 31, 2020 | -$88.41M | – |
| FY2019 | Dec 31, 2019 | -$119.32M | – |
| FY2018 | Dec 31, 2018 | -$75.69M | – |
| FY2017 | Dec 31, 2017 | -$54.86M | – |
| FY2016 | Dec 31, 2016 | -$25.58M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$57.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$57.31M | – |
| Q4 FY2025 | Dec 31, 2025 | -$49.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$48.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$40.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$35.18M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$26.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.84M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$34.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.38M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.03M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.89M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.35M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.97M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$32.33M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.72M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.97M | – |
| Q1 FY2019 | Mar 31, 2019 | -$30.30M | – |
| Q4 FY2018 | Dec 31, 2018 | -$22.39M | – |
| Q3 FY2018 | Sep 30, 2018 | -$19.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.18M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.97M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.16M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.70M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.89M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.11M | – |
See a number that looks wrong?